



Express Mail Label No. EV 175966982 US

PTO/SB/30 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11-12-03

Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

<i>RCE/1600</i>	Application Number	09/839,779
	Filing Date	April 20, 2001
	First Named Inventor	Amin Kassis
	Art Unit	1651
	Examiner Name	Jon P. Weber
	Attorney Docket Number	U0381-00001RCE

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____
ii. Other _____

- b. Enclosed

- | | |
|---|--|
| i. <input checked="" type="checkbox"/> Amendment/Reply | iii. <input type="checkbox"/> Information Disclosure Statement (IDS) |
| ii. <input type="checkbox"/> Affidavit(s)/ Declaration(s) | iv. <input type="checkbox"/> Other _____ |

2. **Miscellaneous**

- a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

- a. period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
b. Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

- a. Deposit Account No. 04-1679

- i. RCE fee required under 37 CFR 1.17(e)

- ii. Extension of time fee (37 CFR 1.136 and 1.17)

- iii. Other Any deficiency in the enclosed check(s) _____

- b. Check in the amount of \$ 440 enclosed

- c. Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Melanie S. McPeek Goddard	Registration No. (Attorney/Agent)	46,732
Signature	<i>Melanie S. McPeek Goddard</i>		
	Date	11/10/03	

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Melanie S. McPeek Goddard, Registration No. 46,732
Signature	Date April 20, 2001

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

11/13/2003 ADMESS1 00000004 09039779
01 FC:2B01



PATENT
EXPRESS MAIL LABEL NO. EV 175966982 US

ATTORNEY DOCKET NO. U0381-00001RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Amin Kassis

Examiner: Jon P. Weber

Serial No.: 09/839,779

Group Art Unit: 1651

Filed: April 20, 2001

For: METHODS FOR TUMOR DIAGNOSIS AND THERAPY

I, MELANIE S. MCPEEK GODDARD, ESQ., REGISTRATION NO. 46,732, CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS EXPRESS MAIL POST OFFICE TO ADDRESSEE SERVICE LABEL NO. EV175966982US UNDER 37 CFR 1.10 IN AN ENVELOPE ADDRESSED TO: BOX NON-FEE AMENDMENT, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON DC 20231.

11/10/03
ON Melanie S. McPeek Goddard
MELANIE S. MCPEEK GODDARD, ESQ.

Mail Stop RCE
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PRELIMINARY AMENDMENT ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

This preliminary amendment is filed with an RCE in further response to the final official action mailed July 8, 2003, and Advisory Action mailed October 6, 2003.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.